Dana Philpott, Canadian Human Immunology Network, University of Toronto, Canada
Dana Philpott is an Associate Professor in the Department of Immunology at the University of Toronto and co-director of the Host-Microbiome Research Network with the support of the Canadian Foundation for Innovation.
Dr. Philpott obtained her PhD from the University of Toronto, where she studied host-pathogen interactions, focusing on enteropathogenic Escherichia coli infection of epithelial cells. She then did her post-doctoral work at the Institut Pasteur under the direction of Dr. Philippe Sansonetti and later became a group leader at this institute. Dr. Philpott was recruited to Toronto in 2006.
The research focus in Dr. Philpott’s laboratory is to understand how Nod-like receptors influence gut homeostasis and how this might impact infection and disease pathogenesis. A particular interest in the laboratory is understanding Crohn’s disease pathogenesis by studying the function of genes that have been linked to the development of this disease, including NOD2 and ATG16L1, as well as their interplay with the gut microbiota. Dr. Philpott has over 150 publications, a number of them in high profile journals. Her discoveries include identification of the peptidoglycan ligands for NOD1 and NOD2 (along with Dr. Gabriel Nunez), uncovering a role for NOD2 and ATG16L1 in bacterial autophagy and regulation of NOD-driven inflammatory responses by ATG16L1. She has received a number of awards for research, including the EMBO Young Investigator Award, a Howard Hughes International Scholar award, and Canadian Association for Gastroenterology Young Investigator Award.
Research in the Philpott laboratory is funded by the Canadian Institutes for Health Research, Natural Sciences and Engineering Research Council of Canada and a grant from Crohn’s and Colitis Canada / Vertex Pharmaceuticals.
« Go Back